BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22930220)

  • 1. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women.
    Schwartz T; Stark A; Pang J; Awuah B; Kleer CG; Quayson S; Kingman S; Aitpillah F; Abantanga F; Jiagge E; Oppong JK; Osei-Bonsu E; Martin I; Yan X; Toy K; Adjei E; Wicha M; Newman LA
    Cancer; 2013 Feb; 119(3):488-94. PubMed ID: 22930220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
    Proctor E; Kidwell KM; Jiagge E; Bensenhaver J; Awuah B; Gyan K; Toy K; Oppong JK; Kyei I; Aitpillah F; Osei-Bonsu E; Adjei E; Ohene-Yeboah M; Brewer RN; Fondjo LA; Owusu-Afriyie O; Wicha M; Merajver S; Kleer C; Newman L
    Ann Surg Oncol; 2015 Nov; 22(12):3831-5. PubMed ID: 25743329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
    Morimoto K; Kim SJ; Tanei T; Shimazu K; Tanji Y; Taguchi T; Tamaki Y; Terada N; Noguchi S
    Cancer Sci; 2009 Jun; 100(6):1062-8. PubMed ID: 19385968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
    Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations.
    Jiagge E; Jibril AS; Davis M; Murga-Zamalloa C; Kleer CG; Gyan K; Divine G; Hoenerhoff M; Bensenhave J; Awuah B; Oppong J; Adjei E; Salem B; Toy K; Merajver S; Wicha M; Newman L
    J Glob Oncol; 2018 Oct; 4():1-8. PubMed ID: 30307804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
    DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
    Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas.
    Demir H; Dulgar O; Gulle BT; Turna H; Ilvan S
    Bosn J Basic Med Sci; 2018 Nov; 18(4):313-319. PubMed ID: 29924962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer.
    Nalwoga H; Arnes JB; Wabinga H; Akslen LA
    Br J Cancer; 2010 Jan; 102(2):369-75. PubMed ID: 20010944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC).
    Ma F; Li H; Li Y; Ding X; Wang H; Fan Y; Lin C; Qian H; Xu B
    Medicine (Baltimore); 2017 Apr; 96(14):e6561. PubMed ID: 28383433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of aldehyde dehydrogenase 1-positive stem cells in benign mammary tissue from women with and without breast cancer.
    Isfoss BL; Holmqvist B; Alm P; Olsson H
    Histopathology; 2012 Mar; 60(4):617-33. PubMed ID: 22260461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
    Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer.
    Li H; Ma F; Wang H; Lin C; Fan Y; Zhang X; Qian H; Xu B
    Int J Biol Markers; 2013 Dec; 28(4):e357-64. PubMed ID: 24338721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
    Shima H; Kida K; Adachi S; Yamada A; Sugae S; Narui K; Miyagi Y; Nishi M; Ryo A; Murata S; Taniguchi H; Ichikawa Y; Ishikawa T; Endo I
    Breast Cancer Res Treat; 2018 Aug; 170(3):507-516. PubMed ID: 29693231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome.
    Tan EY; Thike AA; ; Tan PH
    Br J Cancer; 2013 Jul; 109(1):109-13. PubMed ID: 23787917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.
    Kuroda T; Hirohashi Y; Torigoe T; Yasuda K; Takahashi A; Asanuma H; Morita R; Mariya T; Asano T; Mizuuchi M; Saito T; Sato N
    PLoS One; 2013; 8(6):e65158. PubMed ID: 23762304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.
    Heerma van Voss MR; van der Groep P; Bart J; van der Wall E; van Diest PJ
    Cell Oncol (Dordr); 2011 Feb; 34(1):3-10. PubMed ID: 21336637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
    Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 regulates human mammary stem/progenitor cell fate.
    Liu S; Ginestier C; Charafe-Jauffret E; Foco H; Kleer CG; Merajver SD; Dontu G; Wicha MS
    Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1680-5. PubMed ID: 18230721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.